	US 12,459,991 B2
	Compositions and methods for using bispecific antibodies to bind complement and a target antigen
Christos Kyratsous, Irvington, NY (US); Chia-Yang Lin, Scarsdale, NY (US); Andrew J. Murphy, Croton-on-Hudson, NY (US); Brinda Prasad, Princeton, NJ (US); and Neil Stahl, Carmel, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Appl. No. 17/430,117
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
PCT Filed Feb. 12, 2020, PCT No. PCT/US2020/017889 § 371(c)(1), (2) Date Aug. 11, 2021, PCT Pub. No. WO2020/167919, PCT Pub. Date Aug. 20, 2020.
Claims priority of provisional application 62/804,358, filed on Feb. 12, 2019.
Prior Publication US 2022/0153819 A1, May 19, 2022 Prior Publication US 2024/0254208 A2, Aug. 1, 2024
Int. Cl. C07K 16/12 (2006.01); A61K 39/00 (2006.01); A61P 31/04 (2006.01); A61P 31/16 (2006.01); C07K 16/10 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/1271 (2013.01) [A61K 39/00 (2013.01); A61P 31/04 (2018.01); A61P 31/16 (2018.01); C07K 16/1018 (2013.01); C07K 16/1214 (2013.01); C07K 16/2878 (2013.01); C07K 16/2887 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01)]

7 Claims

1. An isolated bispecific antigen binding molecule comprising:

(i) a first antigen-binding domain that binds CD20 on an immune cell, wherein the first antigen binding domain comprises:

(A) a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 34; and

(B) a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 10; and

(ii) a second antigen-binding domain that binds complement component C1q, wherein the second antigen binding domain comprises:

(A) an HCVR comprising the amino acid sequence of SEQ ID NO: 2; and

(B) an LCVR comprising the amino acid sequence of SEQ ID NO: 10.